News

Sionna Therapeutics is forging ahead in the new year with its preclinical and clinical programs aimed at developing small molecules — such as SION-638 — as possible treatments for cystic fibrosis (CF). An ongoing Phase 1 trial, now enrolling participants, is testing SION-638 in healthy volunteers. Dosing…

A novel inhaled antibiotic that Spexis is developing to treat infections of Pseudomonas aeruginosa — the key bacterial agent of lung infections in cystic fibrosis (CF) — showed a good safety profile in a first trial conducted in healthy volunteers, the company announced. “The first clinical data with our inhaled…

Living closer to composting sites, where solid urban waste is collected and stored, may increase the risk of more severe disease for adults with cystic fibrosis (CF), according to a U.K. study. Close proximity to such sites was linked with worse lung function and more fungal infections among adults. The…

Despite widespread use of telehealth, fewer cystic fibrosis (CF) patients in the U.S. met the recommendations for routine follow-up during the COVID-19 pandemic in 2020 than in 2019. However, the use of telehealth was related to higher adherence to aspects of CF care that can be evaluated remotely. “In…

Physical activity increases fat-free mass — the lean mass in muscles, organs, bones, ligaments and tendons — in adolescents with cystic fibrosis (CF), according to a recent study. The findings also showed that fat-free mass was significantly lower in those with CF-related liver disease. The study, “…

Pseudomonas aeruginosa bacteria can become resistant to the antibiotic tobramycin by clumping into more and larger aggregates and making more of a protective sugar molecule called Psl, a study reported. It used samples of sputum from a small group of children with cystic fibrosis (CF) who received inhaled…

Cystic Fibrosis News Today brought you daily coverage of the latest scientific discoveries, treatment advances, and clinical trials related to cystic fibrosis (CF) this past year. We look forward to continuing to offer you the most up-to-date information in 2023. Here are the 10 most-read CF news articles of 2022,…

Treatment with CFTR modulators was safe during pregnancy and breastfeeding in two women with cystic fibrosis (CF), according to a recent report. Despite being advised to stop treatment, both women continued on their CFTR modulator during pregnancy and breastfeeding without any safety concerns. According to the researchers, this…

Treatment with Trikafta improved insulin secretion and body weight within one year in people with cystic fibrosis (CF), according to a small analysis. Despite these findings, there were no consistent treatment-related improvements in measures relating to CF-related diabetes, or CFRD, a common complication among children and adults…

The Phase 1b/2a clinical trial SWARM–Pa, testing Armata Pharmaceuticals‘ experimental phage therapy AP-PA02 in people with cystic fibrosis (CF) who have chronic Pseudomonas aeruginosa infections, is complete, Armata announced. Data will now be analyzed, and top-line results are expected early in the new year. “We are very pleased to…